Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
about
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysisBisphosphonates and other bone agents for breast cancerPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerPrevention and treatment of bone fragility in cancer patientBisphosphonates in breast cancerAssessment of fracture risk in women with breast cancer using current vs emerging guidelines.Aromatase inhibitors-induced bone loss in early breast cancer.Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.The evolving role of zoledronic acid in early breast cancerThe best of both worlds - managing the cancer, saving the bone.Increased fracture rate in women with breast cancer: a review of the hidden risk.Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.Prevention of bone metastases and management of bone health in early breast cancer.Metastasis and bone loss: advancing treatment and prevention.Bisphosphonates: do we know their role in adjuvant breast cancer treatment?Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells.Update on medications with adverse skeletal effectsAdjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for managementOptimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian GuidelineAge effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trialTreatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.The management of osteoporosis in breast cancer survivors.Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trialHistomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary resultsPrevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN TrialPrevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trialItalian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy.Current and emerging treatment strategies for breast cancer-induced bone loss.Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.Skeletal manifestations of treatment of breast cancer.The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis.Emerging drugs for the management of cancer treatment induced bone loss.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGChallenges in clinical patient management.The use of bisphosphonates in cancer treatment.
P2860
Q21132670-970971FD-50DD-4EDD-85B8-2B55D14A48E6Q24203656-B9ED8D5F-1D6D-4F10-93DF-340CEB039FEDQ26746212-C33BBE54-CA56-4DD1-9EAA-452A73F013CBQ26775765-7475A9E2-FDF9-48B7-975C-7FEE271D3A43Q26859326-4749991E-880E-40CF-B629-752E7B7823FFQ33723674-C488E47B-E3BC-4478-ABA7-11B8395189A2Q33752867-13DA3B29-5335-45F5-973D-7D291DF9B074Q33787731-FCE47F06-2993-467E-ADF3-01416C75A9C9Q33889548-0314D21A-AEC9-4D97-8268-3F81599E36D4Q33915978-8032988D-6033-4088-A717-3CE205CB69CCQ33920055-68AD8CB2-BABA-45EC-9DFC-6E60716EF7F9Q34004925-99688612-1765-4758-BACC-BAB21347461DQ34173455-99EB7AC3-2E7D-4E28-8BFA-014DADA4C4A1Q34613485-41EBDABC-D14A-4489-AF9C-A7CF7FA72166Q34617837-1D9B1058-173E-431E-BCF8-180800EDF6CCQ34632094-CDDC4E99-11F3-4F8D-9010-FE52B737AF9BQ34680563-003CDF68-A3E5-472E-BCB5-055D1A4D42D2Q34731247-4F7D20C3-FC43-4590-ADCB-09F4FD71E387Q34748485-94DE50BE-4F9F-42EF-B6A7-0A41F33D0596Q35076216-3F45DCBD-E26F-4642-AC1C-193DBD63C4AFQ35558893-9B7887D4-A8E9-4325-8E65-F46787484038Q35583788-A5A664DD-E6A2-4849-82A2-74C9A6047F9BQ35750472-F3D62E03-DB95-4A33-BA67-4757C4634BB4Q36162366-1853A331-6B42-4302-9E1C-34496A9776E6Q36187103-DA4B8DEB-C0AE-49AD-88ED-F457A1E0C3A4Q36405775-DCAAC13C-64F5-4EE2-BBE8-77EC8FF51FCBQ36491348-B6D3D087-5DB1-4FE0-AF89-F1BCB88D394DQ36491435-049BC08A-602F-4CC5-9FEF-705CFB550437Q36491519-E43242AF-995A-47AF-86BC-00A3CB566552Q36616992-85C19FE1-A6C0-4A6F-9BFD-3D02A5F69EFDQ37135281-D0C85FA9-E00B-4C52-ABB7-D28E21C72634Q37350988-B13225AA-9FF5-44C9-98A2-EF2054EE4A6FQ37355790-B04D939D-335E-4CC5-9DF3-2538ACC5746FQ37585294-C378B6C7-82F4-4A61-B797-D5342B6DF29EQ37630298-2C5F1E39-E783-4622-88EF-A1B2CF6DA1CCQ37699857-9EF6AD22-6DAD-4C15-9FE3-9B67545AA7E9Q37727235-7AE0F2B3-16F7-42DA-A5A7-352B96F2A21BQ37742180-E2129108-02AD-43DB-B459-BE6E837F5817Q37775020-EA9B9665-34D5-42DE-9CED-632594DEEEB7Q37800183-C62BEA04-617B-4D98-A55C-D063299284C3
P2860
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Prevention of anastrozole-indu ...... tor therapy for breast cancer.
@en
Prevention of anastrozole-indu ...... tor therapy for breast cancer.
@nl
type
label
Prevention of anastrozole-indu ...... tor therapy for breast cancer.
@en
Prevention of anastrozole-indu ...... tor therapy for breast cancer.
@nl
prefLabel
Prevention of anastrozole-indu ...... tor therapy for breast cancer.
@en
Prevention of anastrozole-indu ...... tor therapy for breast cancer.
@nl
P2093
P1476
Prevention of anastrozole-indu ...... itor therapy for breast cancer
@en
P2093
David Dodwell
James E Lester
Janet E Brown
Omprakash P Purohit
Robert E Coleman
Rosemary A Hannon
Ruth Thorpe
Sandra A Gutcher
Susan P Ellis
P304
P356
10.1158/1078-0432.CCR-07-5101
P407
P50
P577
2008-10-01T00:00:00Z